Catalent, Inc. (CTLT)
USD 63.48
(0.0%)
USD 63.48
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 4.54 Billion USD | 12.61% |
| 2023 | 4.31 Billion USD | 3.4% |
| 2022 | 4.17 Billion USD | 31.74% |
| 2021 | 3.16 Billion USD | 7.5% |
| 2020 | 2.94 Billion USD | 2.16% |
| 2019 | 2.88 Billion USD | 8.81% |
| 2018 | 2.64 Billion USD | 28.92% |
| 2017 | 2.05 Billion USD | 12.13% |
| 2016 | 1.83 Billion USD | -1.68% |
| 2015 | 1.86 Billion USD | -30.58% |
| 2014 | 2.68 Billion USD | 1.08% |
| 2013 | 2.65 Billion USD | 0.62% |
| 2012 | 2.64 Billion USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 4.32 Billion USD | -1.05% |
| 2024 Q2 | 4.95 Billion USD | 14.74% |
| 2024 FY | 4.54 Billion USD | 5.38% |
| 2024 Q4 | 4.54 Billion USD | -7.87% |
| 2024 Q3 | 4.93 Billion USD | -0.52% |
| 2023 FY | 4.31 Billion USD | 3.4% |
| 2023 Q3 | 4.26 Billion USD | 0.95% |
| 2023 Q4 | 4.31 Billion USD | 1.22% |
| 2023 Q2 | 4.22 Billion USD | 3.0% |
| 2023 Q1 | 4.09 Billion USD | -1.75% |
| 2022 Q2 | 4.19 Billion USD | -0.8% |
| 2022 Q3 | 4.15 Billion USD | -0.81% |
| 2022 FY | 4.17 Billion USD | 31.74% |
| 2022 Q1 | 4.22 Billion USD | 33.45% |
| 2022 Q4 | 4.17 Billion USD | 0.34% |
| 2021 Q3 | 3.14 Billion USD | 5.56% |
| 2021 FY | 3.16 Billion USD | 7.5% |
| 2021 Q1 | 2.98 Billion USD | 1.36% |
| 2021 Q2 | 2.98 Billion USD | -0.05% |
| 2021 Q4 | 3.16 Billion USD | 0.52% |
| 2020 Q3 | 2.92 Billion USD | 3.62% |
| 2020 Q1 | 2.85 Billion USD | -0.84% |
| 2020 Q2 | 2.82 Billion USD | -1.19% |
| 2020 Q4 | 2.94 Billion USD | 0.62% |
| 2020 FY | 2.94 Billion USD | 2.16% |
| 2019 Q1 | 2.2 Billion USD | -16.75% |
| 2019 FY | 2.88 Billion USD | 8.81% |
| 2019 Q4 | 2.88 Billion USD | 36.22% |
| 2019 Q3 | 2.11 Billion USD | -0.64% |
| 2019 Q2 | 2.13 Billion USD | -3.43% |
| 2018 Q3 | 2.7 Billion USD | 1.27% |
| 2018 Q4 | 2.64 Billion USD | -2.11% |
| 2018 FY | 2.64 Billion USD | 28.92% |
| 2018 Q1 | 2.08 Billion USD | 1.35% |
| 2018 Q2 | 2.67 Billion USD | 28.31% |
| 2017 Q1 | 1.83 Billion USD | 0.28% |
| 2017 FY | 2.05 Billion USD | 12.13% |
| 2017 Q3 | 2.02 Billion USD | 1.2% |
| 2017 Q4 | 2.05 Billion USD | 1.47% |
| 2017 Q2 | 2 Billion USD | 8.88% |
| 2016 FY | 1.83 Billion USD | -1.68% |
| 2016 Q4 | 1.83 Billion USD | -0.66% |
| 2016 Q3 | 1.84 Billion USD | -0.18% |
| 2016 Q2 | 1.84 Billion USD | -0.62% |
| 2016 Q1 | 1.85 Billion USD | -0.23% |
| 2015 Q2 | 1.9 Billion USD | 7.03% |
| 2015 Q1 | 1.78 Billion USD | -33.7% |
| 2015 FY | 1.86 Billion USD | -30.58% |
| 2015 Q4 | 1.86 Billion USD | 0.38% |
| 2015 Q3 | 1.85 Billion USD | -2.54% |
| 2014 Q2 | 2.67 Billion USD | -0.08% |
| 2014 Q1 | 2.67 Billion USD | 0.64% |
| 2014 FY | 2.68 Billion USD | 1.08% |
| 2014 Q4 | 2.68 Billion USD | 0.43% |
| 2014 Q3 | 2.67 Billion USD | 0.09% |
| 2013 Q4 | 2.65 Billion USD | 0.0% |
| 2013 FY | 2.65 Billion USD | 0.62% |
| 2013 Q1 | - USD | 0.0% |
| 2012 FY | 2.64 Billion USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 2.52 Billion USD | -80.15% |
| Bausch Health Companies Inc. | 21.93 Billion USD | 79.283% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -917.917% |
| Elanco Animal Health Incorporated | 5.73 Billion USD | 20.764% |
| Perrigo Company plc | 3.63 Billion USD | -25.11% |
| Teva Pharmaceutical Industries Limited | 18.48 Billion USD | 75.407% |
| Zoetis Inc. | 6.56 Billion USD | 30.759% |